Project Grant H8G47507

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

Federal Cooperative Agreement Summary IMPACT-CETR Vaccine Development Initiative The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a $14.73 million Cooperative Agreement on August 19, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance multicomponent vaccines targeting multidrug-resistant bacterial pathogens. The Center of Excellence for Translational Research (IMPACT-CETR) will develop novel vaccines...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $661,313 to Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, to support research on universal influenza A virus (IAV) vaccine development through elicitation of broadly neutralizing antibodies (BNABs). Principal Investigator Dr. Daniel Lingwood and Co-Investigator Dr. Batista will engineer nanoparticle immunogens...

This federal Project Grant award of $360,000 from the National Science Foundation's (NSF) Division of Mathematical Sciences and the CDC Coronavirus and Other Respiratory Viruses Division aims to improve policymaking processes for mitigating the transmission of respiratory pathogens, such as during the COVID-19 pandemic. The principal investigators will develop and study game theoretical mathematical models, simulation tools, and numerical approaches that can be adapted to specific public...

Federal Cooperative Agreement Summary The University of Maryland, Baltimore received a $1.55 million Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 20, 2025, with completion targeted for July 31, 2030. The award funds a prospective clinical trial investigating the molecular determinants of vaccine-induced antibody durability—specifically, why certain...

Federal Project Grant Award Summary Massachusetts General Hospital received a $676,666 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 3, 2025, with a completion date of August 31, 2030. The award funds research into spatial and temporal adjuvant delivery mechanisms designed to enhance messenger RNA (mRNA) vaccine efficacy and durability. The project will...

The National Council On Aging, Inc. was awarded a $150 million project grant from the Administration for Community Living under the Special Programs for the Aging, Title IV, and Title II, Discretionary Projects program (CFDA #93.048). The grant will support the COVID-19 AND INFLUENZA VACCINE UPTAKE INITIATIVE FOR OLDER ADULTS AND PEOPLE WITH DISABILITIES through May 18, 2024. Under this initiative, the National Council On Aging will provide $150 million in funding to 26 sub-awardees across the...